Hyoscine hydrobromide

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
See also: Hyoscine butylbromide
Hyoscine hydrobromide
L-Scopolamin.svg
Scopolamine structure.png
Systematic (IUPAC) name
(–)-(S)-3-Hydroxy-2-phenylpropionic acid (1R,2R,4S,7S,9S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl ester
Clinical data
Trade names Transdermscop, Kwells
AHFS/Drugs.com monograph
Pregnancy
category
  • AU: B2
  • US: C (Risk not ruled out)
Legal status
Routes of
administration		 transdermal, ocular, oral, subcutaneous, intravenous, sublingual, rectal, buccal transmucousal, intramuscular
Pharmacokinetic data
Bioavailability 0.13–8% (Oral),[1] 3% (Rectal)[1]
Metabolism Liver
Biological half-life 4.5 hours[2]
Excretion Kidney
Identifiers
CAS Number 51-34-3 YesY
ATC code A04AD01 (WHO) N05CM05, S01FA02
PubChem CID: 5184
IUPHAR/BPS 330
DrugBank DB00747 YesY
ChemSpider 10194106 YesY
UNII DL48G20X8X YesY
KEGG D00138 YesY
ChEBI CHEBI:16794 YesY
ChEMBL CHEMBL1201024 N
Chemical data
Formula C17H21NO4
Molecular mass 303.353 g/mol
 NYesY (what is this?)  (verify)

Hyoscine hydrobromide, also known as scopolamine hydrobromide,[3] is a medication used in the treatment of motion sickness and postoperative nausea and vomiting.[4][5]

It can make people sleepy.[6] It is a tropane alkaloid drug with muscarinic antagonist effects. Hyoscine hydrobromide exerts its effects by acting as a competitive antagonist at muscarinic acetylcholine receptors; it is thus classified as an anticholinergic, antimuscarinic drug. Although it is usually referred to as a nonspecific antagonist,[7] there is indirect evidence for m1-receptor subtype specificity.[8]

It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system.[9] Scopolamine is named after the plant genus Scopolia.[10] The name "hyoscine" is from the scientific name for henbane, Hyoscyamus niger.[11]

Medical use

Scopolamine has a number of uses in medicine, where it is used to treat:[12][13]

It is sometimes used as a premedication (especially to reduce respiratory tract secretions) to surgery, mostly commonly by injection.[12][13]

Pregnancy

Scopolamine crosses the placenta and is a pregnancy category C medication, meaning a risk to the fetus cannot be ruled out. Either studies in animals have revealed adverse effects on the fetus (teratogenic or embryocidal effects or other) and no controlled studies in women have been made, or studies in women and animals are not available. Drugs should be given only if the potential benefits justify the potential risk to the fetus. It may cause respiratory depression and/or neonatal hemorrhage when used during pregnancy, and some animal studies did report adverse events.[citation needed] Transdermal scopolamine has been used as an adjunct to epidural anesthesia for Caesarean delivery without adverse CNS effects on the newborn. Except when used prior to Caesarean section, use it during pregnancy only if the benefit to the mother outweighs the potential risk to the fetus.

Breastfeeding

Scopolamine enters breast milk by secretion. Although no human studies exist to document the safety of scopolamine while nursing, the manufacturer recommends caution be used if scopolamine be administered to a nursing woman.[17]

Elderly

Scopolamine use in the elderly can increase the likelihood of experiencing adverse effects from the drug. This phenomenon is especially true of the elder population who are also concurrently on several other medications. Avoid scopolamine use in this age group due to potent anticholinergic adverse effects and uncertain effectiveness.[18]

Adverse effects

Adverse effect incidence:[1][4][5][19]

Uncommon (0.1%-1% incidence) adverse effects include
Rare (<0.1% incidence) adverse effects include
Unknown frequency adverse effects include

Overdose

Physostigmine is an acetylcholinesterase inhibitor that readily crosses the blood-brain barrier, and has been used as an antidote to treat the CNS depression symptoms of scopolamine overdose.[20] Other than this supportive treatment, gastric lavage and induced emesis (vomiting) are usually recommended as treatments for overdoses.[19] The symptoms of overdose include:[1][19]

Hospitalizations

About one in five emergency room admissions for poisoning in Bogotá, Colombia, have been attributed to scopolamine.[21] In June 2008, more than 20 people were hospitalized with psychosis in Norway after ingesting counterfeit rohypnol tablets containing scopolamine.[22]

Interactions

Due to interactions with metabolism of other drugs, scopolamine can cause significant unwanted side effects when taken with other medications. Specific attention should be paid to other medications in the same pharmacologic class as scopolamine, also known as anticholinergics. The following medications could potentially interact with the metabolism of scopolamine: analgesics/pain medications, ethanol, zolpidem, thiazide diuretics, buprenorphine, anticholinergic drugs such as tiotropium, etc.

Mechanisms of administration

Scopolamine can be administered orally, subcutaneously, ophthalmically and intravenously, as well as via a transdermal patch.[23] The transdermal patch (e.g., Transderm Scōp) for prevention of nausea and motion sickness employs scopolamine base, and is effective for up to three days.[24] The oral, ophthalmic, and intravenous forms have shorter half-lives and are usually found in the form scopolamine hydrobromide (for example in Scopace, soluble 0.4 mg tablets or Donnatal).

NASA is currently developing a nasal administration method. With a precise dosage, the NASA spray formulation has been shown to work faster and more reliably than the oral form.[25]

Biosynthesis in plants

It is among the secondary metabolites of plants from Solanaceae (nightshade) family of plants, such as henbane, jimson weed (Datura), angel's trumpets (Brugmansia), and corkwood (Duboisia).[10][26]

The steps of the biosynthesis of scopolamine are:

History

One of the earlier alkaloids isolated from plant sources, scopolamine has been in use in its purified forms (such as various salts, including hydrochloride, hydrobromide, hydroiodide and sulfate), since its isolation by the German scientist Albert Ladenburg in 1880, and as various preparations from its plant-based form since antiquity and perhaps prehistoric times. Following the description of the structure and activity of scopolamine by Ladenburg, the search for synthetic analogues of and methods for total synthesis of scopolamine and/or atropine in the 1930s and 1940s resulted in the discovery of diphenhydramine, an early antihistamine and the prototype of its chemical subclass of these drugs, and pethidine, the first fully synthetic opioid analgesic, known as Dolatin and Demerol amongst many other trade names.

Scopolamine was used in conjunction with morphine, oxycodone, or other opioids from before 1900 into the 1960s to put mothers in labor into a kind of "twilight sleep". The analgesia from scopolamine plus a strong opioid is deep enough to allow higher doses to be used as a form of anaesthesia.

Scopolamine mixed with oxycodone (Eukodal) and ephedrine was marketed by Merck as SEE (from the German initials of the ingredients) and Scophedal starting in 1928, and the mixture is sometimes mixed on site on rare occasions in the area of its greatest historical usage, namely Germany and Central Europe.

Scopolamine was also one of the active ingredients in Asthmador, an over-the-counter (OTC) smoking preparation marketed in the 1950s and 1960s claiming to combat asthma and bronchitis. In November 1990, the US Food and Drug Administration forced OTC products with scopolamine and several hundred other ingredients that had allegedly not been proved effective off the market. Scopolamine shared a small segment of the OTC sleeping pill market with diphenhydramine, phenyltoloxamine, pyrilamine, doxylamine, and other first-generation antihistamines, many of which are still used for this purpose in drugs such as Sominex, Tylenol PM, NyQuil, etc.

Society and culture

Names

Hyoscine hydrobromide is the International Nonproprietary Name while scopolamine hydrobromide is the United States Adopted Name. Other names include levo-duboisine and burundanga.[21]

Recreational use

While it is occasionally used recreationally for its hallucinogenic properties, the experiences are often mentally and physically extremely unpleasant, and frequently physically dangerous, so repeated use is rare.[29]

Interrogation

The effects of scopolamine were studied by criminologists in the early 20th century.[30] In 2009, it was proven that Czechoslovak communist state security secret police used scopolamine at least three times to obtain confessions from alleged antistate conspirators.[31] Because of a number of undesirable side effects, scopolamine was shortly disqualified as a truth serum.[32]

In 1910, scopolamine was detected in the remains believed to be those of Cora Crippen, wife of Dr. Hawley Harvey Crippen, and was accepted at the time as the cause of her death, since her husband was known to have bought some at the start of the year.[33]

Crime

It is unclear if the claims of use of scopolamine in crime is true or not.[34] The drug is known to produce loss of memory of events recently before exposure and sleepiness, similar to the effect of benzodiazepines or alcohol poisoning, but claims of the drug "removing free will" are dubious.

Scopolamine has been used under the name "burundanga" in Venezuelan and Thailand resorts in order to drug and then rob tourists. In 2008, Vice News aired an episode called Colombian Devil's Breath recounting the use of scopolamine by Colombian criminals as a suggestion drug. The two-part investigation contains multiple first-hand accounts of its use,[35] including claims that small amounts blown into people's faces turn them into "mindless zombies".[35] While there are rumors that delivery mechanisms include using pamphlets and flyers laced with the drug, not enough is readily absorbed through the skin to have an effect.[34] However, spiked alcoholic drinks are occasionally used.

Per the United States State Department (March 4, 2012):

One common and particularly dangerous method that criminals use in order to rob a victim is through the use of drugs. The most common has been scopolamine. Unofficial estimates put the number of annual scopolamine incidents in Colombia at approximately 50,000. Scopolamine can render a victim unconscious for 24 hours or more. In large doses, it can cause respiratory failure and death. It is most often administered in liquid or powder form in foods and beverages. The majority of these incidents occur in night clubs and bars, and usually men, perceived to be wealthy, are targeted by young, attractive women. To avoid becoming a victim of scopolamine, one should never accept food or beverages offered by strangers or new acquaintances or leave food or beverages unattended. Victims of scopolamine or other drugs should seek immediate medical attention.[36]

Research

Hyoscine hydrobromide has been studied as an antidepressant with a number of small studies finding positive results.[37][38][39]

References

  1. ↑ 1.0 1.1 1.2 1.3 "Buscopan Tablets - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Boehringer Ingelheim Limited. 11 September 2013. Retrieved 22 October 2013.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  2. ↑ Putcha, L.; Cintrón, N. M.; Tsui, J.; Vanderploeg, J. M.; Kramer, W. G. (1989). "Pharmacokinetics and Oral Bioavailability of Scopolamine in Normal Subjects". Pharmacology Research. 6 (6): 481–485. doi:10.1023/A:1015916423156. PMID 2762223.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  3. ↑ Juo, Pei-Show (2001). Concise Dictionary of Biomedicine and Molecular Biology (2nd ed.). Hoboken: CRC Press. p. 570. ISBN 9781420041309.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  4. ↑ 4.0 4.1 "TRANSDERM SCOP (scopalamine) patch, extended release [Baxter Healthcare Corporation]". DailyMed. Baxter Healthcare Corporation. April 2013. Retrieved 22 October 2013.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  5. ↑ 5.0 5.1 "DBL™ HYOSCINE INJECTION BP". TGA eBusiness Services. Hospira Australia Pty Ltd. 30 January 2012. Retrieved 22 October 2013.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  6. ↑ Handbook of Palliative Care (3rd ed.). New York: Wiley. 2012. p. 570. ISBN 9781118426814.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  7. ↑ http://scholar.google.com/scholar?q=scopolamine+nonselective&btnG=&hl=en&as_sdt=0%2C11
  8. ↑ Burke, RE (1986). "The relative selectivity of anticholinergic drugs for the M1 and M2 muscarinic receptor subtypes". Movement Disorders. 1 (2): 135–144. doi:10.1002/mds.870010208. PMID 2904117.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  9. ↑ "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  10. ↑ 10.0 10.1 The Chambers Dictionary. Allied Publishers. 1998. pp. 788, 1480. ISBN 978-81-86062-25-8.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  11. ↑ Cattell, Henry Ware (1910). Lippincott's new medical dictionary: a vocabulary of the terms used in medicine, and the allied sciences, with their pronunciation, etymology, and signification, including much collateral information of a descriptive and encyclopedic character. Lippincott. p. 435. Retrieved 25 February 2012.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  12. ↑ 12.0 12.1 Joint Formulary Committee (2013). British National Formulary (BNF) (65 ed.). London, UK: Pharmaceutical Press. pp. 49, 266, 822, 823. ISBN 978-0-85711-084-8.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  13. ↑ 13.0 13.1 Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  14. ↑ Bitterman, N.; Eilender, E.; Melamed, Y. (1991). "Hyperbaric Oxygen and Scopolamine". Undersea Biomedical Research. 18 (3): 167–174. PMID 1853467. Retrieved 13 August 2008.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  15. ↑ Williams, T. H.; Wilkinson, A. R.; Davis, F. M.; Frampton, C. M. (1988). "Effects of Transcutaneous Scopolamine and Depth on Diver Performance". Undersea Biomedical Research. 15 (2): 89–98. PMID 3363755.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  16. ↑ http://www.medicinenet.com/scopolamine_drops-ophthalmic/article.htm
  17. ↑ Briggs (1994). Drugs in Pregnancy and Lactation. Baltimore, MD: Williams and Wilkins. pp. 777–778.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  18. ↑ Flicker; Ferris (1992). "Hypersensitivity to scopolamine in the elderly". Psychopharmacology (Berl). 107 (2–3): 437–441. doi:10.1007/bf02245172. PMID 1615141.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  19. ↑ 19.0 19.1 19.2 "Kwells 300 microgram tablets - Summary of Product Characteristics". electronic Medicines Compendium. Bayer plc. 7 January 2008. Retrieved 22 October 2013.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  20. ↑ Paul G. Barash; et al., eds. (2009). Clinical anesthesia (6 ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. p. 346. ISBN 978-0-7817-8763-5.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  21. ↑ 21.0 21.1 Uribe-Granja, Manuel; Moreno-López, Claudia L.; Zamora S., Adriana; Acosta, Pilar J. (September 2005). "Perfil epidemiológico de la intoxicación con burundanga en la clínica Uribe Cualla S. A. de Bogotá, D. C". Acta Neurológica Colombiana (pdf)|format= requires |url= (help) (in Spanish). 21 (3): 197–201.CS1 maint: unrecognized language (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  22. ↑ "Bilsykemedisin i falske rohypnol-tabletter". Aftenposten.no.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  23. ↑ White, P. F.; Tang, J.; Song, D.; et al. (2007). "Transdermal Scopolamine: An Alternative to Ondansetron and Droperidol for the Prevention of Postoperative and Postdischarge Emetic Symptoms". Anesthesia and Analgesia. 104 (1): 92–96. doi:10.1213/01.ane.0000250364.91567.72. PMID 17179250.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  24. ↑ "Transderm Scop patch prescribing information".<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  25. ↑ "NASA Signs Agreement to Develop Nasal Spray for Motion Sickness".<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  26. ↑ Muranaka, T.; Ohkawa, H.; Yamada, Y. (1993). "Continuous Production of Scopolamine by a Culture of Duboisia leichhardtii Hairy Root Clone in a Bioreactor System". Applied Microbiology and Biotechnology. 40 (2–3): 219–223. doi:10.1007/BF00170370.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  27. ↑ 27.0 27.1 27.2 Ziegler, J.; Facchini, P. J. (2008). "Alkaloid Biosynthesis: Metabolism and Trafficking". Annual Review of Plant Biology. 59 (1): 735–769. doi:10.1146/annurev.arplant.59.032607.092730. PMID 18251710.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  28. ↑ Li, R.; Reed, D. W.; Liu, E.; Nowak, J.; Pelcher, L. E.; Page, J. E.; Covello, P. S. (2006). "Functional Genomic Analysis of Alkaloid Biosynthesis in Hyoscyamus niger Reveals a Cytochrome P450 Involved in Littorine Rearrangement". Chemistry & Biology. 13 (5): 513–520. doi:10.1016/j.chembiol.2006.03.005. PMID 16720272.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  29. ↑ Freye, E. (2010). "Toxicity of Datura Stramonium". Pharmacology and Abuse of Cocaine, Amphetamines, Ecstasy and Related Designer Drugs. Netherlands: Springer. pp. 217–218. doi:10.1007/978-90-481-2448-0_34. ISBN 978-90-481-2447-3.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  30. ↑ House, R. E. (September 1922). "The Use of Scopolamine in Criminology". Texas State Journal of Medicine. 18: 256–263.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
    Reprinted in: House, Robert E. (July–August 1931). "The Use of Scopolamine in Criminology". American Journal of Police Science. Northwestern University School of Law. 2 (4): 328–336. doi:10.2307/1147361. JSTOR 1147361.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  31. ↑ Gazdík, J.; Navara, L. (8 August 2009). "Svědek: Grebeníček vězně nejen mlátil, ale dával jim i drogy" (in Czech). iDnes. Retrieved 10 August 2009. Unknown parameter |trans_title= ignored (help)CS1 maint: unrecognized language (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  32. ↑ Bimmerle, George (22 September 1993). "'Truth' Drugs in Interrogation". Central Intelligence Agency. Retrieved 14 June 2012.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  33. ↑ Young, Filson, ed. (1920). The Trial of Hawley Harvey Crippen. Notable Trials Series. Edinburgh: William Hodge & Company. p. xxvii; see also evidence, pp. 68–77. OCLC 22125100. Retrieved 6 August 2015.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  34. ↑ 34.0 34.1 The Guardian (2 September 2015). "'Devil's breath' aka scopolamine: can it really zombify you?". Retrieved 10 November 2015.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  35. ↑ 35.0 35.1 "Colombian Devil's Breath". Vice News. 12 May 2012. Retrieved 22 November 2015.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  36. ↑ "Colombia 2012 Crime and Safety Report: Cartagena". Overseas Security Advisory Council, United States Department of State. 4 March 2012. Retrieved 6 August 2015.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  37. ↑ Drevets, WC; Zarate CA, Jr; Furey, ML (15 June 2013). "Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review". Biological psychiatry. 73 (12): 1156–63. doi:10.1016/j.biopsych.2012.09.031. PMID 23200525.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  38. ↑ Hasselmann, H (2014). "Scopolamine and depression: a role for muscarinic antagonism?". CNS & neurological disorders drug targets. 13 (4): 673–83. doi:10.2174/1871527313666140618105710. PMID 24938776.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  39. ↑ Jaffe, RJ; Novakovic, V; Peselow, ED (2013). "Scopolamine as an antidepressant: a systematic review". Clinical neuropharmacology. 36 (1): 24–6. doi:10.1097/wnf.0b013e318278b703. PMID 23334071.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
Retrieved from "https://infogalactic.com/w/index.php?title=Hyoscine_hydrobromide&oldid=19036"